Korro Bio, a biopharmaceutical company specializing in RNA editing-based genetic medicines, announced that its top executives will participate in two upcoming investor conferences in May 2026. The events include the HCW 4th Annual BioConnect Nasdaq Investor Conference on May 19 and the RBC Capital Markets Global Healthcare Conference on May 20. These presentations will highlight Korro's innovative OPERA platform, which enables precise RNA editing to develop treatments for rare and common diseases. This exposure aims to attract investor interest and provide updates on Korro's progress in advancing its genetic medicine pipeline.
East West Bancorp is set to report strong Q2 2026 earnings with an expected EPS of $2.61 and revenue of $785.94 million, reflecting an 11.8% revenue increase and 14.5% EPS growth year-over-year. The bank shows robust financial health with expanding d...
AerCap has selected GE Aerospace's GEnx-1B engines to power 15 additional Boeing 787 Dreamliners, reinforcing its position as the largest owner of these aircraft. The GEnx engine is known for its high reliability and long service life, with a 99.98% ...
Crédit Agricole Brie Picardie conducted share buybacks totaling 13,057 shares from July 13 to July 17, 2026, with daily volumes ranging from 1,605 to 5,095 shares. These transactions were carried out under Article 5 of the Market Abuse Regulation (MA...
Northland Securities has increased its price target for Ouster to $60, reflecting a 55.88% upside from the current price. Ouster, a company specializing in digital LiDAR sensors for autonomous vehicles and robotics, aims to reach EBITDA breakeven wit...
Bank of America recently launched its BofA Rewards™ Program, enrolling over 3 million clients in just seven weeks, signaling strong customer interest. Meanwhile, Representative James A. Himes sold Bank of America shares valued between $1,001 and $15,...
